INVESTORS PUSHING BACK ON MYLAN EXECUTIVE PAY

Put off by what they see as exorbitant pay for Mylan executives, some big pension funds are attempting to block the reelection of a number of board members, including chairman and former CEO Robert Coury, who received $100 million last year. They say huge paychecks were awarded to executives even as backlash from consumers and the U.S. government escalated over prices Mylan charged for its EpiPen emergency allergy treatment.